SCHEMBL2938439

SCHEMBL2938439

CC(C)Cc1cc(CN2CC(=O)N(c3ccc(OC(F)(F)F)cc3)C2=O)ccn1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 5/20 0.43
PPARA Q07869 5/20 0.43
PPARG P37231 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 1/20 0.38
ENPP2 Q13822 2/20 0.37
NTRK1 P04629 1/20 0.37
LIPE Q05469 2/20 0.36
IGF1R P08069 1/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 1/20 0.36
PLA2G10 O15496 1/20 0.35
PLA2G2A P14555 1/20 0.35
PLA2G5 P39877 1/20 0.35
POLB P06746 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GRM2 Q14416 1/20 0.35
TAS2R8 Q9NYW2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934945 0.89 IGF1R (0.46) PPARDPPARAPPARGSMN1; SMN2ALDH1A1
SCHEMBL2940014 0.87 PPARD (0.44) PPARDPPARAPPARGSMN1; SMN2ALDH1A1
SCHEMBL2931264 0.87 ENPP2 (0.45) PPARDPPARAPPARGSMN1; SMN2ALDH1A1
SCHEMBL2936001 0.87 PPARD (0.45) PPARDPPARAPPARGSMN1; SMN2ALDH1A1
SCHEMBL2936748 0.87 PPARD (0.43) PPARDPPARAPPARGSMN1; SMN2ALDH1A1
SCHEMBL2937986 0.86 PPARD (0.43) PPARDPPARAPPARGSMN1; SMN2ALDH1A1
SCHEMBL2940538 0.86 PPARD (0.48) PPARDPPARAPPARGSMN1; SMN2ALDH1A1
SCHEMBL2931615 0.85 PPARD (0.44) PPARDPPARAPPARGSMN1; SMN2ALDH1A1
SCHEMBL2936037 0.85 IGF1R (0.49) PPARDPPARAPPARGSMN1; SMN2ALDH1A1
SCHEMBL2939334 0.85 IGF1R (0.52) PPARDPPARAIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 PPARD 3189/4885PPARA 4338/4885PPARG 4175/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA PPARD 3572/4885PPARA 4692/4885PPARG 4645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.